Logo image of CGON

CG ONCOLOGY INC (CGON) Stock Fundamental Analysis

USA - NASDAQ:CGON - US1569441009 - Common Stock

41.91 USD
-1.15 (-2.67%)
Last: 10/22/2025, 4:20:00 PM
41.91 USD
0 (0%)
After Hours: 10/22/2025, 4:20:00 PM
Fundamental Rating

3

Taking everything into account, CGON scores 3 out of 10 in our fundamental rating. CGON was compared to 534 industry peers in the Biotechnology industry. CGON has a great financial health rating, but its profitability evaluates not so good. CGON is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CGON has reported negative net income.
In the past year CGON has reported a negative cash flow from operations.
CGON Yearly Net Income VS EBIT VS OCF VS FCFCGON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

CGON has a better Return On Assets (-18.26%) than 77.72% of its industry peers.
Looking at the Return On Equity, with a value of -19.11%, CGON belongs to the top of the industry, outperforming 85.39% of the companies in the same industry.
Industry RankSector Rank
ROA -18.26%
ROE -19.11%
ROIC N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGON Yearly ROA, ROE, ROICCGON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

CGON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGON Yearly Profit, Operating, Gross MarginsCGON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

CGON does not have a ROIC to compare to the WACC, probably because it is not profitable.
CGON has more shares outstanding than it did 1 year ago.
CGON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CGON Yearly Shares OutstandingCGON Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
CGON Yearly Total Debt VS Total AssetsCGON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CGON has an Altman-Z score of 63.14. This indicates that CGON is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 63.14, CGON belongs to the best of the industry, outperforming 97.57% of the companies in the same industry.
There is no outstanding debt for CGON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 63.14
ROIC/WACCN/A
WACC9.33%
CGON Yearly LT Debt VS Equity VS FCFCGON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 22.15 indicates that CGON has no problem at all paying its short term obligations.
The Current ratio of CGON (22.15) is better than 95.88% of its industry peers.
CGON has a Quick Ratio of 22.15. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 22.15, CGON belongs to the top of the industry, outperforming 95.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.15
Quick Ratio 22.15
CGON Yearly Current Assets VS Current LiabilitesCGON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CGON have decreased by -9.62% in the last year.
The Revenue for CGON has decreased by -34.72% in the past year. This is quite bad
CGON shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -52.09% yearly.
EPS 1Y (TTM)-9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.86%
Revenue 1Y (TTM)-34.72%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 32.63% on average over the next years. This is a very strong growth
Based on estimates for the next years, CGON will show a very strong growth in Revenue. The Revenue will grow by 276.70% on average per year.
EPS Next Y-54.58%
EPS Next 2Y-27.46%
EPS Next 3Y-7.55%
EPS Next 5Y32.63%
Revenue Next Year-75.23%
Revenue Next 2Y829.31%
Revenue Next 3Y463.91%
Revenue Next 5Y276.7%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CGON Yearly Revenue VS EstimatesCGON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CGON Yearly EPS VS EstimatesCGON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGON. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGON Price Earnings VS Forward Price EarningsCGON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGON Per share dataCGON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as CGON's earnings are expected to decrease with -7.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.46%
EPS Next 3Y-7.55%

More info and screens

0

5. Dividend

5.1 Amount

CGON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CG ONCOLOGY INC

NASDAQ:CGON (10/22/2025, 4:20:00 PM)

After market: 41.91 0 (0%)

41.91

-1.15 (-2.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners104.81%
Inst Owner Change0.05%
Ins Owners1.16%
Ins Owner Change0%
Market Cap3.20B
Revenue(TTM)551.00K
Net Income(TTM)-128081000
Analysts82.22
Price Target65.99 (57.46%)
Short Float %15.85%
Short Ratio12.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.35%
Min EPS beat(2)-15.32%
Max EPS beat(2)-9.38%
EPS beat(4)1
Avg EPS beat(4)-9.5%
Min EPS beat(4)-33.19%
Max EPS beat(4)19.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-88.02%
Min Revenue beat(2)-100%
Max Revenue beat(2)-76.04%
Revenue beat(4)1
Avg Revenue beat(4)65.12%
Min Revenue beat(4)-100%
Max Revenue beat(4)496.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.41%
PT rev (3m)3.11%
EPS NQ rev (1m)0.32%
EPS NQ rev (3m)-22.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-45.32%
Revenue NY rev (1m)14.28%
Revenue NY rev (3m)-43.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5799.71
P/FCF N/A
P/OCF N/A
P/B 4.77
P/tB 4.77
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-2.31
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.01
BVpS8.79
TBVpS8.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.26%
ROE -19.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.41%
Cap/Sales 43.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.15
Quick Ratio 22.15
Altman-Z 63.14
F-Score3
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.86%
EPS Next Y-54.58%
EPS Next 2Y-27.46%
EPS Next 3Y-7.55%
EPS Next 5Y32.63%
Revenue 1Y (TTM)-34.72%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-75.23%
Revenue Next 2Y829.31%
Revenue Next 3Y463.91%
Revenue Next 5Y276.7%
EBIT growth 1Y-51.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.05%
EBIT Next 3Y-20.32%
EBIT Next 5YN/A
FCF growth 1Y-72.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.32%
OCF growth 3YN/A
OCF growth 5YN/A